Amid Eli Lilly's efforts to strengthen its global manufacturing network, the Indianapolis pharma giant is splashing more than $1 billion into its Indian operations, with plans to tap local partners for production deals.
The investment will come to fruition over the coming years and is aimed at boosting the supply of key Eli Lilly drugs for obesity, diabetes, Alzheimer's disease, cancer and autoimmune conditions through local contract manufacturers, Reuters reported Monday.
In a statement to Fierce Pharma, the company confirmed a planned investment of "more than $1 billion" in contract manufacturing in India, but did not provide further details.
Part of the investment will go to a new manufacturing and quality facility in the city of Hyderabad to oversee Lilly's network of contract manufacturers, according to Reuters.
The drugmaker has been operating in India since 1993 at its commercial site in Guraugram Gurgaon and also has a “critical global hub” in Bengaluru, according to its website. Earlier this year, the company announced plans to establish a global capability center (GCC) in Hyderabad.
Since 2020, the drugmaker has spent more than $55 billion on its global manufacturing capabilities. The latest overseas investment comes after President Donald Trump announced 100% tariffs on imported branded drugs, a policy that exempts companies that are working to build U.S. manufacturing plants.
Stateside, Lilly has been swelling its footprint with billions of dollars in investments. In February, the company pledged $27 billion in four new U.S. production facilities. Since then, the company has unveiled plans for massive facilities in Virginia and Texas.